Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Rhodes Pharmaceuticals, L.P. Clear all
Completed Phase 3 Interventional Results available

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

NCT01269463
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Methylphenidate Hydrochloride Extended Release Capsule, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 5, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

NCT01239030
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Methylphenidate Hydrochloride Extended Release Capsules, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
6 Years to 18 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
Little Rock, Arkansas • Irvine, California • National City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 5, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD

NCT02470234
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 5 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 5, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of PRC-063 in Adult ADHD Patients

NCT02139124
View directory record Official record
Conditions
ADHD
Interventions
Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
33
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 5, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

PRC-063 in Adolescent ADHD

NCT02139111
View directory record Official record
Conditions
ADHD
Interventions
Placebo, PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg, PRC-063 85 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
12 Years to 17 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 5, 2026, 5:31 PM EDT
Not listed Phase 4 Interventional

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

NCT02677519
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 5, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

NCT02555150
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
PRC-063, lisdexamfetamine dimesylate, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 5, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD

NCT02683265
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 5, 2026, 5:31 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of PG101 for Dry Eye Syndrome

NCT02078661
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
PG101
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 5, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

NCT02168127
View directory record Official record
Conditions
ADHD
Interventions
Drug: PRC-063, PRC-063
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
12 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 5, 2026, 5:31 PM EDT
Completed Phase 3 Interventional

PRC-063 in an ADULT Workplace Environment

NCT02225639
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
PRC-063 25 mg, Placebo, PRC-063 35 mg, PRC-063 45 mg, PRC-063 55 mg, PRC-063 70 mg, PRC-063 85 mg, PRC-063 100 mg
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Newport Beach, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 5, 2026, 5:31 PM EDT